A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent.
D000284:Administration, Oral; D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D001590:Benztropine / Q000008:administration & dosage / Q000627:therapeutic use; D001593:Benzyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005069:Evaluation Studies as Topic; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D007273:Injections, Intramuscular; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy*; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D010881:Piperidones / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D011618:Psychotic Disorders / Q000188:drug therapy; D014326:Tropanes / Q000008:administration & dosage / Q000627:therapeutic use
D000978:Antiparkinson Agents; D001593:Benzyl Compounds; D003692:Delayed-Action Preparations; D010276:Parasympatholytics; D010880:Piperidines; D010881:Piperidones; D010919:Placebos; D014326:Tropanes; D001590:Benztropine; D006220:Haloperidol